Why the study?
With widespread direct oral anticoagulant use, a rapid assay is urgently needed to exclude clinically relevant plasma levels and guide acute clinical decision-making.
Does the DOAC Dipstick test accurately exclude clinically relevant plasma levels of DOACs in patients taking these medications?
Does the DOAC Dipstick test accurately exclude clinically relevant plasma levels of DOACs in patients taking these medications?
An expert consensus proposes an algorithm using the DOAC Dipstick test to rapidly and reliably exclude clinically relevant DOAC levels in acute care settings lacking 24/7 quantitative assays.
Answers are grounded in this paper and cite their sources.
May support rapid DOAC exclusion in emergencies; leaves open need for prospective trials before clinical adoption.
BACKGROUND: With the widespread use of direct oral anticoagulants (DOACs), there is an urgent need for a rapid assay to exclude clinically relevant plasma levels. Accurate and rapid determination of DOAC levels would guide medical decision-making to (1) determine the potential contribution of the DOAC to spontaneous or trauma-induced hemorrhage; (2) identify appropriate candidates for reversal, or (3) optimize the timing of urgent surgery or intervention. METHODS AND RESULTS: The DOAC Dipstick test uses a disposable strip to identify factor Xa- or thrombin inhibitors in a urine sample. Based on the results of a systematic literature search followed by an analysis of a simple pooling of five retrieved clinical studies, the test strip has a high sensitivity and an acceptably high negative predictive value when compared with levels measured with liquid chromatography tandem mass spectrometry or calibrated chromogenic assays to reliably exclude plasma DOAC concentrations ≥30 ng/mL. CONCLUSION: Based on these data, a simple algorithm is proposed to enhance medical decision-making in acute care indications useful primarily in hospitals not having readily available quantitative tests and 24/7. This algorithm not only determines DOAC exposure but also differentiates between factor Xa and thrombin inhibitors to better guide clinical management.
No takes yet. Share an insight, caveat, or question.
Harenberg et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: